NU1025

Research use only, not for human use.

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

NU1025 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor, which potentiates the cytotoxicity of a panel of mechanistically diverse anti-cancer agents in L1210 cells. NU1025 enhanced the cytotoxicity of the DNA-methylating agent MTIC, gamma-irradiation and bleomycin 3.5-, 1.4- and 2-fold respectively.

NU1025 (0.2 mM) pretreatment restores cell viability to approximately 73% and 82% in H2O2 and SIN-1 injured cells, respectively.NU1025 enhances the cytotoxicity of the DNA-methylating agent MTIC, γ-irradiation and bleomycin 3.5-, 1.4- and 2-fold respectively in L1210 cells. The recovery from potentially lethal γ-irradiation damage cytotoxicity in plateau-phase cells is also inhibited by NU 1025. NU1025 causes a marked retardation of DNA repair. Cell Viability Assay Cell Line:PC12 cells Concentration:0.2 mM Incubation Time:6.5 hours Result:Restored cell viability to approximately 73% and 82% in H2O2 and SIN-1 injured cells.

NU1025 (1-3 mg/kg; intraperitoneal injection; male Sprague Dawley rats) treatment at 1 and 3 mg/kg reduces total infarct volume to 25% and 45%, respectively, when administered 1 h before reperfusion. NU1025 also produces significant improvement in neurological deficits. Neuroprotection with NU1025 is associated with reduction in PAR accumulation, reversal of brain NAD depletion and reduction in DNA fragmentation. Animal Model:Male Sprague Dawley rats (250-270 g) induced focal cerebral ischemia Dosage:1 mg/kg, 3 mg/kg Administration:Intraperitoneal injection Result:At 1 and 3 mg/kg, reduced total infarct volume to 25% and 45%, respectively.

NU-1025 | NU1025 | NU 1025

Metabolic Enzyme/Protease

DPP

PARP

Neurological Disease

——

90417-38-2

176.17

C9H8N2O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (567.63 mM)

CC1=NC2=C(C=CC=C2O)C(=O)N1

8-Hydroxy-2-methyl-4(3H)-quinazolin?one

(-20℃)

With Ice Pack

≥ 2 years